Extended-Release Naltrexone Improves Viral Suppression among Incarcerated Persons Living with HIV with Opioid Use Disorders Transitioning to the Community: Results of a Double-Blind, Placebo-Controlled Randomized Trial

Eitemau Tebyg

• Design and methods of a double blind randomized placebo-controlled trial of extended-release naltrexone for HIV-infected, opioid dependent prisoners and jail detainees who are transitioning to the community
  gan: Di Paola, Angela, et al.
  Cyhoeddwyd: (2014)
• Extended-release naltrexone reduces alcohol consumption among released prisoners with HIV disease as they transition to the community
  gan: Springer, Sandra A., et al.
  Cyhoeddwyd: (2017)
• An Evaluation of Hepatic Enzyme Elevations Among HIV-Infected Released Prisoners Enrolled in Two Randomized Placebo-Controlled Trials of Extended Release Naltrexone
  gan: Vagenas, Panagiotis, et al.
  Cyhoeddwyd: (2014)
• Design and methods of a double blind randomized placebo-controlled trial of extended-release naltrexone for alcohol dependent and hazardous drinking prisoners with HIV who are transitioning to the community
  gan: Springer, Sandra A., et al.
  Cyhoeddwyd: (2013)
• Corrigendum to ‘An Evaluation of Hepatic Enzyme Elevations Among HIV-Infected Released Prisoners Enrolled in Two Randomized Placebo-Controlled Trials of Extended Release Naltrexone’ [Journal of Substance Abuse Treatment 47 (2014) 35–40]
  gan: Vagenas, Panagiotis, et al.
  Cyhoeddwyd: (2017)